The Geriatric Medicines Industry sales study offers a comprehensive analysis on diverse features including production capacities, Geriatric Medicines demand, product developments, sales revenue generation and Geriatric Medicines market outlook across the globe.
170 page market research report by Fact.MR, (Leading business and competitive intelligence provider) on global Geriatric Medicines market sales initiates with an outlook of the market, followed by the scrutiny of the demand and consumption volumes and share and size of various end-use segments
Fact.MR, a market research and competitive intelligence provider, states that the sales of geriatric medicines will reach US$ 768 Mn by the end of 2021. As per the report, geriatric medicines for cardiovascular ailments will account for 45% revenue until 2031. By the end of the forthcoming decade, the global market for geriatric medicines will likely surpass US$ 1.5 Bn.
Download Sample Copy of This Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=4746
The readability score of the Geriatric Medicines market demand report is good as it offers chapter-wise layout with each section divided into a smaller sections.
The report encompasses graphs and tables to show the entire assembling. Pictorial demonstration of the definite and estimated values of key segments is visually appealing to readers.
This Geriatric Medicines market outlook report explicates on vital dynamics such as the drivers, restraints and opportunities for key players and competitive analysis of Geriatric Medicines along with key stakeholders as well as emerging players associated with the manufacturing of product.
The Key trends Analysis of Extended Geriatric Medicines market also provides dynamics that are responsible for influencing the future sales and demand of over the forecast period.
Key Companies Profiled
- AstraZeneca
- Merck & Co, Inc.
- Pfizer, Inc.
- Novartis AG
- Bristol-Myers Squibb Company
- Sanofi S.A.
- GlaxoSmithKline Plc.
- Eli Lilly and Company
- Abbott Laboratories
- Boehringer Ingelheim GmbH
Questionnaire answered in the market outlook report of Geriatric Medicines include:
- What is the key strategy deployed by large players to maximize Geriatric Medicines marketgrowth?
- What are the main challenges faced by players in the Geriatric Medicines market demand?
- With the advent of technological advancement, how will the Geriatric Medicines market landscape change over the forecast period?
- What does player bring to the table, which is unique as a strategy, and is easy to emulate for new investors in the Geriatric Medicines market size?
How will be insights and market estimations provided in the Fact.MR report on the demand of Geriatric Medicines make a difference?
- The study takes a closer look at the major economic turmoil, with a focus on the recent COVID-19 pandemic disruptions
- The assessment of key growth dynamics highlights the attractiveness of new automation technologies and offers readers insight on the prospect of these during the forecast period
- The study tries to offer a balance perspective of the opportunities in mature and the most lackluster markets
- Provides scrutiny of the industry trends that have shaped recent government policies
- Provides an account of major breakthroughs in all segments that might change the course of the market considerably
- Provides an incisive analysis of socio-political milieu in which the key markets operate, and how will that influence the lucrativeness of the overall Geriatric Medicines market
- Analyzes how collaborations and partnerships among players from different industries shape the key growth dynamics in the near future
- Evaluates the role of various stages of funding on new growth avenues in key regional markets
Competitive Landscape
Prominent geriatric medicines manufacturers are emphasizing on a wide array of expansion strategies, comprising of acquisitions, new product launches and collaborations. Some prominent developments in the geriatric medicines industry as follows:
- In August 2021, Pfizer announced that it will acquire Trillium Therapeutics, a clinical stage immune oncology company. The acquisition will work towards improvising the treatments of cancer. According to Pfizer, the deal is likely to be worth US$ 2.26 billion.
- In October 2021, Merck & Co. Inc. published preliminary results of the clinical trials for its Molnupiravir anti-COVID-19 drug. As per the findings, patients administered with this anti-viral halved chances of hospitalization amongst patients exhibiting mild or moderate symptoms. Those administered with this drug showed 100% recovery
Key Segments Covered
· Therapeutic Category
o Analgesic Geriatric Medicines
o Anti-Hypertensive Geriatric Medicines
o Statin Geriatric Medicines
o Anti-Diabetic Geriatric Medicines
o Proton Pump Inhibitor Geriatric Medicines
o Anticoagulant Geriatric Medicines
o Anti-Psychotic Geriatric Medicines
o Anti-Depressant Geriatric Medicines
· Condition
o Geriatric Medicines for Cardiovascular Ailments
o Geriatric Medicines for Arthritis
o Geriatric Medicines for Diabetes
o Geriatric Medicines for Neurological Disorders
o Geriatric Medicines for Cancer
o Geriatric Medicines for Osteoporosis
o Geriatric Medicines for Respiratory Disorders
o Geriatric Medicines for Other Conditions
· Distribution Channel
o Geriatric Medicines Sales via Hospital Pharmacies
o Geriatric Medicines Sales via Retail Pharmacies
o Geriatric Medicines Sales via Online Pharmacies
Get Full Access of Complete Report:
https://www.factmr.com/checkout/4746
